Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 92% Improvement Relative Risk HCQ for COVID-19  Rogado et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 17 patients in Spain Lower mortality with HCQ (p=0.02) Rogado et al., Lung Cancer, May 2020 Favors HCQ Favors control

Covid-19 and lung cancer: A greater fatality rate?

Rogado et al., Lung Cancer, doi:10.1016/j.lungcan.2020.05.034
May 2020  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 17 hospitalized lung cancer patients showing lower mortality with HCQ+AZ treatment.
risk of death, 91.6% lower, RR 0.08, p = 0.02, treatment 1 of 8 (12.5%), control 7 of 9 (77.8%), NNT 1.5, odds ratio converted to relative risk, multivariate logistic regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rogado et al., 29 May 2020, retrospective, Spain, peer-reviewed, 9 authors.
This PaperHCQAll
Covid-19 and lung cancer: A greater fatality rate?
Jacobo Rogado, Cristina Pangua, Gloria Serrano-Montero, Berta Obispo, Almudena Martín Marino, Mar Pérez-Pérez, Ana López-Alfonso, Pedro Gullón, Miguel Ángel Lara
Lung Cancer, doi:10.1016/j.lungcan.2020.05.034
Background: Currently there are no reported series determining the Covid-19 infected lung cancer patient´s characteristics and outcome that allow us to clarify strategies to protect our patients. In our study we determine whether exists differences in cumulative incidence and severity of Covid-19 infection between lung cancer patients visiting our Medical Oncology department and the reference population of our center (320,000 people), in the current epicenter of the pandemic in Europe (Madrid, Spain). We also describe clinical and demographic factors associated with poor prognosis and Covid-19 treatment outcomes. Patients and methods: We retrospectively reviewed 1878 medical records of all Covid-19 patients who were admitted at Hospital Universitario Infanta Leonor of Madrid between March 5, 2020 and April 7, 2020, in order to detect cumulative incidence of Covid-19 in lung cancer patients. We also described Covid-19 treatment outcome, mortality and associated risk factors using univariate and multivariate logistic regression analysis. Results: 17/1878 total diagnosis in our center had lung cancer (0.9 %) versus 1878/320,000 of the total reference population (p = 0.09). 9/17 lung cancer patients with Covid-19 diagnosis died (52.3 %) versus 192/ 1878 Covid-19 patients in our center (p < 0.0001). Dead lung cancer patients were elderly compared to survivors: 72 versus 64.5 years old (p = 0.12). Combined treatment with hydroxychloroquine and azithromycin improves the outcome of Covid-19 in lung cancer patients, detecting only 1/6 deaths between patients under this treatment versus others treatment, with statistical significance in the univariate and multivariate logistic regression (OR 0.04, p = 0.018). Conclusions: Lung cancer patients have a higher mortality rate than general population. Combined hydroxychloroquine and azithromycin treatment seems like a good treatment option. It is important to try to minimize visits to hospitals (without removing their active treatments) in order to decrease nosocomial transmission.
Authors contributions J.R. contributed to the conception and design of the study, data acquisition, statistical analysis, interpretation of the data and writing of the manuscript. C.P and G.S.M contributed to the conception and design of the study, interpretation of the data and writing of the manuscript. B.O., A.M.M., M.P.P., A.L.A. contributed to the acquisition of the data. P.G. contributed to the statistical analysis and interpretation of the data. M.A.L. contributed to the conception and design of the study, interpretation of the data and writing of the manuscript. All authors reviewed and approved the final version of the manuscript. Declaration of Competing Interest The authors declare no conflict of interest for the present work.
Banna, Curioni-Fontecedro, Friedlaender, How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere, ESMO Open
Conti, Ronconi, Caraffa, Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies, J. Biol. Regul. Homeost. Agents
Cortiula, Pettke, Bastoletti, Managing COVID-19 in the oncology clinic and avoiding the distraction effect, Ann. Oncol
Garassino, TERAVOLT (thoracic cancER interational coVid 19 cOLlaboraTion): first results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies, Abstract
Li, Guan, Wu, Early Transmission Dynamics In Wuhan, China, of Novel Coronavirus-Infected PneumoniaEarly transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N. Engl. J. Med
Liang, Guan, Chen, Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol
Sidaway, COVID-19 and cancer: what we know so far, Nat. Rev. Clin. Oncol
Wang, Horby, Hayden, A novel coronavirus outbreak of global health concern, Lancet
Yin, Wunderink, MERS, SARS and other coronaviruses as causes of pneumonia, Respirology
Yu, Ouyang, Chua, SARS-CoV-2 transmission in patients with Cancer at a tertiary care hospital in Wuhan, China, JAMA Oncol
Zhang, Zhu, Xie, Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China, Ann. Oncol
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop